Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.57 |
| ▸ | CNR1 | P21554 | 7/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19638882 | 1.00 | CNR2 (0.57) | CNR2CNR1SLC6A3KDM4ENPC1 | |
| SCHEMBL29410253 | 0.85 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL19638929 | 0.85 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL29387398 | 0.85 | CNR2 (0.57) | CNR2CNR1SLC6A3 | |
| SCHEMBL19638844 | 0.85 | CNR2 (0.57) | CNR2CNR1SLC6A3 | |
| SCHEMBL10654147 | 0.76 | PGR (0.55) | CNR2CNR1SLC6A3KDM4E | |
| SCHEMBL29385124 | 0.75 | CNR2 (0.58) | CNR2CNR1 | |
| SCHEMBL19638822 | 0.75 | CNR2 (0.58) | CNR2CNR1 | |
| SCHEMBL6013329 | 0.74 | KDM4E (0.59) | CNR2CNR1SLC6A3KDM4E | |
| SCHEMBL27799854 | 0.74 | ALDH1A1 (0.55) | CNR2CNR1SLC6A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076921-A1 | Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis | PIKE THERAPEUTICS INC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-20250312359-A1 | Transdermal Delivery of Tetrahydrocannabinol | Pike Therapeutics Inc. (CA) | 2025-10-09 | — | — | US | disclosed |
| US-20250248948-A1 | Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain | PIKE THERAPEUTICS INC (CA) | 2025-08-07 | — | — | US | disclosed |
| US-20250186363-A1 | Pharmaceutical Compositions and Methods for Treating Parkinson's Disease | PIKE THERAPEUTICS INC (CA) | 2025-06-12 | — | — | US | disclosed |
| EP-4558135-A1 | CONTINUOUS DELIVERY SYSTEMS COMPRISING A CANNABINOID AND MEDICINAL USES THEREOF | Pike Therapeutics Inc. (CA) | 2025-05-28 | — | — | EP | disclosed |
| CN-119923256-A | Continuous delivery system comprising cannabinoids and medical uses thereof | 长矛治疗股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-12268699-B2 | Transdermal delivery of tetrahydrocannabinol | Pike Therapeutics Inc. (CA) | 2025-04-08 | — | — | US | disclosed |
| US-20250009768-A1 | Transdermal Delivery of Tetrahydrocannabinol | Pike Therapeutics Inc. (CA) | 2025-01-09 | — | — | US | disclosed |
| US-12097293-B2 | Transdermal delivery of cannabidiol | Pike Therapeutics Inc. (CA) | 2024-09-24 | — | — | US | disclosed |
| EP-4322931-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | Pike Therapeutics Inc. (CA) | 2024-02-21 | — | — | EP | disclosed |
| EP-4110325-A1 | TRANSDERMAL AND/OR TOPICAL PHARMACEUTICAL FORMULATIONS COMPRISING CANNABIDIOL AND/OR TETRAHYDROCANNABINOL FOR THE TREATMENT OF CHRONIC PAIN | Pike Therapeutics, Inc. (CA) | 2023-01-04 | — | — | EP | disclosed |
| US-20220347151-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | PIKE THERAPEUTICS INC (CA) | 2022-11-03 | — | — | US | disclosed |
| WO-2022219468-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | PIKE THERAPEUTICS, INC. 1219014 B.C. LTD. (CA) | 2022-10-20 | — | — | WO | disclosed |
| EP-4045024-A1 | TRANSDERMAL DELIVERY OF CANNABIDIOL | Pike Therapeutics, Inc., 1219014 B.C. Ltd. (CA) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022118303-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS COMPRISING CBD OR THC FOR THE TREATMENT OF CANCER | PIKE THERAPEUTICS, INC. (CA) | 2022-06-09 | — | — | WO | disclosed |
| US-20220175718-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CANCER | PIKE THERAPEUTICS INC (CA) | 2022-06-09 | — | — | US | disclosed |
| CN-114555068-A | Transdermal administration of cannabidiol | 长矛治疗股份有限公司1219014 B.C.有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022038475-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | PIKE THERAPEUTICS, INC. (CA) | 2022-02-24 | — | — | WO | disclosed |
| US-20220047541-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | Pike Therapeutics Inc. (CA) | 2022-02-17 | — | — | US | disclosed |
| US-20220047525-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF NABILONE ALONE AND IN COMBINATION WITH CANNABINOIDS | PIKE THERAPEUTICS INC (CA) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248948-A1 | Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885SLC6A3 1390/4885 |
| US-20260076921-A1 | Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis | SOST, CNR2, BHMT2 | CNR2 2/4885CNR1 25/4885SLC6A3 1828/4885 |
| US-12097293-B2 | Transdermal delivery of cannabidiol | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885SLC6A3 712/4885 |
| US-20220175718-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CANCER | CNR2, CNR1, DSG1 | CNR2 1/4885CNR1 2/4885SLC6A3 1030/4885 |
| US-20250186363-A1 | Pharmaceutical Compositions and Methods for Treating Parkinson's Disease | PARK7, SNCA, COMT | CNR2 422/4885CNR1 613/4885SLC6A3 60/4885 |
| US-20220347151-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF CHRONIC PAIN | CNR2, TRPV1, CNR1 | CNR2 1/4885CNR1 3/4885SLC6A3 485/4885 |
| US-20220047541-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE | PARK7, SNCA, COMT | CNR2 422/4885CNR1 613/4885SLC6A3 60/4885 |
| US-20250312359-A1 | Transdermal Delivery of Tetrahydrocannabinol | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885SLC6A3 861/4885 |
| US-12268699-B2 | Transdermal delivery of tetrahydrocannabinol | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885SLC6A3 861/4885 |
| US-20220047525-A1 | TRANSDERMAL PHARMACEUTICAL FORMULATIONS OF NABILONE ALONE AND IN COMBINATION WITH CANNABINOIDS | CNR2, CNR1, FAAH | CNR2 1/4885CNR1 2/4885SLC6A3 392/4885 |
| US-20250009768-A1 | Transdermal Delivery of Tetrahydrocannabinol | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885SLC6A3 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.